Giladi Moshe - Feb 27, 2024 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role
Chief Science Officer
Signature
Steven Robbins, as attorney in fact for Giladi, Moshe
Stock symbol
NVCR
Transactions as of
Feb 27, 2024
Transactions value $
$2,107,557
Form type
4
Date filed
2/29/2024, 04:33 PM
Previous filing
Dec 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCR Ordinary Shares Award $833K +51.1K +274.17% $16.30 69.8K Feb 27, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVCR Stock Options (Right to buy) Award $1.27M +78.2K $16.30 78.2K Feb 27, 2024 Ordinary Shares 78.2K $16.30 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.
F2 Options to buy 78,174 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.